NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Polestar Cuts 2026 Outlook After U.S. Ban Adds $130 Million Hit

Polestar lowered 2026 volume guidance to low-to-mid single digits, missed Q2 revenue estimates, and booked about $130 million in U.S. exit costs after being blocked from selling new vehicles.

Polestar Cuts 2026 Outlook After U.S. Ban Adds $130 Million Hit
Photo by Sam Freeman on Unsplash
Already have an account? Sign in.
09/03/2026 · 8:23 AM
PSNY
/ Don’t stop at just one post.

Related↓

Polestar Secures $400M Investment to Strengthen Finances
02/02/2026 · 6:18 AM

Polestar Secures $400M Investment to Strengthen Finances

Polestar announces a $400 million equity investment from global banks, boosting liquidity and supporting future growth after a record sales year.

/ Subscriber only
/ Read more

Feed↓

GSK posts strong lung cancer data at WCLC as it seeks first-line Jideytro approval
Featured/ 09/14/2026 · 9:52 AM

GSK posts strong lung cancer data at WCLC as it seeks first-line Jideytro approval

Jideytro shrank tumors in 94% of untreated ROS1 patients; Ris-Rez cut death risk 54% vs topotecan in China. FDA filing planned this year.

/ Subscriber only
B. Riley Turns Bullish on Capricor Before November Deramiocel Decision
09/14/2026 · 9:17 AM

B. Riley Turns Bullish on Capricor Before November Deramiocel Decision

B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.

/ Subscriber only
FDA Grants Breakthrough Therapy Designation to Armata’s Phage Therapy for Complicated Staph Blood Infections
09/14/2026 · 8:36 AM

FDA Grants Breakthrough Therapy Designation to Armata’s Phage Therapy for Complicated Staph Blood Infections

FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe